If you're only tracking owned properties, you're missing 90% of the story and the critical insights shaping HCP treatment decisions. Comprehensive behavioral intelligence fills this gap, empowering pharmaceutical marketers to make confident, evidence-based investments.
Why Only Tracking Your Owned Properties Misses 90% of the Story
Pharmaceutical marketers have become skilled at optimizing their digital properties. Website analytics can offer detailed insights into visitor behavior, such as time on page, click patterns, and bounce rates. However, HCPs' treatment research journeys are complex and non-linear, involving many sources beyond owned properties.
ZoomRx Digital Journey research indicates that HCPs allocate only 10% of their time to product sites. This means that engagement with owned properties provides an incomplete view of the content shaping treatment decisions. Furthermore, owned-property metrics provide little meaningful insight into competitor engagement.
The Shortcomings of Survey-Based Behavioral Insights
Marketers often turn to primary market research to address these gaps. While surveys can uncover valuable insights about brand and competitor perceptions, they have inherent limitations when used to map actual online behavior.
One significant limitation is recall bias, which is particularly challenging in digital behavior research. HCPs visit nearly 300 unique healthcare-related webpages each week and typically spend less than two minutes on each. Asking them to recall which websites they visited (and what content they engaged with) over any extended period often results in incomplete or inaccurate accounts. The rapid and often unconscious nature of online browsing makes reliable self-reporting difficult.
As a result, surveys struggle to reveal the granular, moment-to-moment patterns of real HCP digital behavior.
Revealing the Complete Digital Journey with a Behavior-First Approach
Today’s measurement tools fall short of addressing these challenges. What’s needed is a hybrid approach – one that combines actual online behavior with primary research. This model offers visibility into HCP engagement across all media channels while linking interactions to performance and competitive benchmarks that matter.
The ZoomRx Digital Journey Tracker provides a comprehensive view of how target HCPs navigate the digital landscape by capturing real-time browsing behavior across all life science websites. It also integrates primary research to measure perceptual shifts, helping marketers understand how digital touchpoints shape treatment decisions and brand perceptions.
By tracking actual behavior, this methodology uncovers key insights such as:
- Which sites HCPs use to research treatment options
- How much time they spend on your content versus competitor content
- How digital interactions influence treatment decisions and brand perception
This approach moves beyond isolated metrics to provide full context around HCP engagement, empowering marketers to identify the most effective channels and direct resources toward the most impactful touchpoints.
Making Confident Decisions with Complete Journey Intelligence
To achieve measurable impact, pharmaceutical marketers need a complete view of the HCP's digital journeys, which traditional methods are not equipped to provide. The ZoomRx Digital Journey Tracker fills this gap by offering comprehensive behavioral intelligence that combines real-world behavior with attitudinal insights.
With this full-spectrum view, marketers gain the clarity needed to make smarter investments, strengthen omnichannel strategy, and drive meaningful engagement beyond owned channels.
Get in touch with us
